For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing ...

Signs of multiple sclerosis may surface years before diagnosis, as patients use healthcare more often for early symptoms.

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

In contrast to traditional measures, such as an increase or worsening of lesions or overall brain atrophy, to signal progression of multiple sclerosis (MS), investigators are proposing atrophied ...

Multiple sclerosis (MS) is a progressive disease of the central nervous system that can cause symptoms throughout the body, including both physical and cognitive symptoms. Obesity in childhood and ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...